{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:09Z","timestamp":1786993989841,"version":"build-2736575974"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Nederlandse Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.mayocp.2024.12.006","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T03:03:21Z","timestamp":1738551801000},"page":"187-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stroke Survivors With Type 2 Diabetes: Repositioning Pioglitazone in an Era Dominated by Gliflozins"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-2897","authenticated-orcid":false,"given":"Navin","family":"Suthahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2024.12.006_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2024.12.006_bib2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jdi.12932","article-title":"Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review","volume":"10","author":"Lau","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"issue":"2","key":"10.1016\/j.mayocp.2024.12.006_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.mayocp.2024.12.006_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mayocp.2024.08.015","article-title":"Cardiovascular outcomes with antidiabetic drugs in people with type 2 diabetes and a prior stroke","volume":"100","author":"Bae","year":"2025","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocp.2024.12.006_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMx070038","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"357","author":"Nissen","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2024.12.006_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"17","key":"10.1016\/j.mayocp.2024.12.006_bib7","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2024.12.006_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.mayocp.2024.12.006_bib9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2024.12.006_bib10","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","volume":"24","author":"Spence","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.mayocp.2024.12.006_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40264-015-0318-4","article-title":"Variation in association between thiazolidinediones and heart failure across ethnic groups: retrospective analysis of large healthcare claims databases in six countries","volume":"38","author":"Roughead","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.mayocp.2024.12.006_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174076","article-title":"Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH","volume":"901","author":"Tahara","year":"2021","journal-title":"Eur J Pharmacol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624006761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624006761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T03:16:46Z","timestamp":1738552606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619624006761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0025619624006761"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.12.006","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stroke Survivors With Type 2 Diabetes: Repositioning Pioglitazone in an Era Dominated by Gliflozins","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.08.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}